UCB

UCB SA

UCB.BR ucb.com + Research + Basket
ISIN BE0003739530
Employees 9,000
Phone 32 2 559 99 99
Fiscal year end December
Address Allée de la Recherche, 60, Brussels, Belgium, 1070
290.20
+0.00 (+0.00%)
EUR · BR
52-week range
197.45
292.20
Trading at 98% of the 52-week range
Market Cap
55.33B
P/E Ratio
25.64
Forward P/E
20.20
Book Value
61.12
Div. Yield
0.51%
% Institutions
39.29%
% Insiders
36.28%

1 Year

+34.8%

3 Year

+330.2%

10 Year

+456.1%
Description

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company offers Cimzia for ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, polyarticular juvenile idiopathic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson's disease and restless legs syndrome. It also provides Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. In addition, the company offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx to treat plaque psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; Fintepla for the treatment of Dravet and Lennox-Gastaut syndrome; and RYSTIGGO and ZILBRYSQ to treat people living with generalized myasthenia gravis. Further, it develops KYGEVVI (doxecitine/doxribtimine) for thymidine kinase 2 deficiency disorder; fenfluramine to treat CDKL5 deficiency disorder, and RETT-Syndrome; dapirolizumab pegol for systemic lupus erythematosus; STACCATO alprazolam for treating stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; and UCB9741 for atopic dermatitis, non cystic fibrosis bronchiectasis, and chronic obstructive pulmonary disease. Additionally, it engages in the contract manufacturing activities. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.

Actions

Add an action for UCB.BR, or sign in to see your action list.

People

▼

Directors & Officers

Name Title Year Born
Dr. Jean-Christophe Tellier CEO & Executive Director 1959
Ms. Sandrine Dufour CFA Executive VP & CFO 1966
Mr. Alistair Henry Executive VP & Chief Scientific Officer 1967
Ms. Denelle J. Waynick Johnson J.D. Executive VP & General Counsel 1967
Mr. Jean-Luc Fleurial Executive VP & Chief Human Resources Officer 1965
Mr. Emmanuel Caeymaex Executive VP & Head of Patient Evidence 1969
Ms. Fiona Du Monceau Executive VP of Patient Impact & Chief Commercial Officer 1978
Ms. Caroline Vancoillie Chief Accounting Officer & Head of Group Finance NA
Gwendoline Ornigg Head of Global Corporate Communication NA
Veronique Toully Head of Sustainability, Corporate Affairs & Enterprise Risk Management NA

Financial Highlights

▼
Market Cap: $55.33B
EBITDA: $3.14B
P/E Ratio: $25.64
PEG Ratio: $1.45
Book Value: $61.12
Dividend/Share: $1.45
Dividend Yield: 0.51%
Earnings/Share: $11.32
Profit Margin: 25.74%
Operating Margin: 33.33%
ROA (TTM): 8.30%
ROE (TTM): 20.57%
Revenue (TTM): $8.52B
Revenue/Share (TTM): $44.77
Earnings Growth (YOY): 134.80%
Revenue Growth (YOY): 22.50%

Valuation Metrics

Enterprise Value: $55.12B
Trailing P/E: 25.64
Forward P/E: 20.20

Shares Statistics

Shares Outstanding: 190.66M
Shares Float: 120.10M
% Insiders: 36.28%
% Institutions: 39.29%

Stock Price History

▼

1 Year Price History

3 Years Price History

10 Years Price History

Max Price History

Financial Charts

▼
Open balance sheet Open capital intensity Download Financials (Excel)

Revenue, Net Income & Operating Cash Flow (Yearly)

Change % vs Prior Year

Revenue, Net Income & Operating Cash Flow (Quarterly)

Change % vs Prior Quarter

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

▼
Open full waterfall Open balance sheet
Line Item
Step Type
Value
Revenue
adjust
$7.74B
Cost of Goods Sold
adjust
$-2.23B
Gross Profit
subtotal
$5.51B
SG&A
adjust
$-264.00M
R&D
adjust
$-1.82B
Other Operating Expense
adjust
$-2.26B
Operating Income
subtotal
$1.17B
Other / Non-Operating Items
adjust
$392.00M
Net Income
subtotal
$1.56B

Earnings Per Share (EPS) History

▼

Financial Ratios

▼

📦 Raw API Data (JSON Explorer)

▼

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about UCB.BR!